Earnings Call Summary | Biolase(BIOL.US) Q1 2024 Earnings Conference
Earnings Call Summary | Biolase(BIOL.US) Q1 2024 Earnings Conference
The following is a summary of the BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript:
以下是BIOLASE, Inc.（BIOL）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
BIOLASE reported a significant growth in consumable sales, marking a 14% increase compared to the same quarter last year, making it one of the strongest quarters in the company's history.
The company achieved a reduction in its adjusted EBITDA loss by 21%, demonstrating improved financial discipline and operational efficiency.
The CEO, John Beaver, expressed optimism towards achieving profitability by the end of the year.
BIOLASE ended the first quarter with a cash balance of $6.4 million and expects to report positive adjusted EBITDA for the full year of 2024.
BIOLASE报告称，消耗品销售大幅增长，与去年同期相比增长了14％，成为该公司历史上最强劲的季度之一。
该公司调整后的息税折旧摊销前利润亏损减少了21％，这表明财务纪律和运营效率得到改善。
首席执行官约翰·比弗对年底之前实现盈利表示乐观。
BIOLASE在第一季度末的现金余额为640万美元，预计2024年全年调整后的息税折旧摊销前利润将为正数。
Business Progress:
业务进展：
A significant portion of BIOLASE's U.S. Waterlase sales (67%) for the quarter was to new customers, with dental specialists accounting for about 42% of these sales.
The company organized and participated in over a hundred promotional events, ranging from webinars to trade shows, aimed at promoting the benefits of laser dentistry.
BIOLASE continued to roll out their unique Waterlase and EPIC academy training programs.
The company's ongoing commercial focus remains on reaching to the estimated 90% of dentists who are yet to adopt all-tissue laser technology.
In the future, the company plans to allocate investments towards revenue-generating activities.
For 2024, BIOLASE has projected a year-over-year revenue growth ranging from 6% to 8%, translating to an estimated full year revenue of between $52 million to $53 million.
BIOLASE本季度美国Waterlase销售额的很大一部分（67％）来自新客户，牙科专家约占这些销售额的42％。
该公司组织并参与了一百多场促销活动，从网络研讨会到贸易展览会，旨在宣传激光牙科的好处。
BIOLASE继续推出其独特的Waterlase和EPIC学院培训计划。
该公司持续的商业重点仍然是向尚未采用全组织激光技术的估计90％的牙医提供服务。
将来，该公司计划将投资分配给创收活动。
BIOLASE预计2024年的收入同比增长6％至8％不等，这意味着全年收入估计在5200万美元至5300万美元之间。
More details: Biolase IR
更多详情： Biolase IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。